MiroBio is a recently launched biologics company with a mission to treat a range of autoimmune and inflammatory disorders. The company is founded by leading immunologists at the University of Oxford who have spent over 15yrs focussed on understanding the mechanisms which underlie T-cell signalling. The technology is based on an IP portfolio of novel antibodies with the ability to activate inhibitory co-receptors on the surface of immune cells, with a deep mechanistic understanding, MiroBio is able to optimise these antibodies to create immune-modulatory therapies which have shown remarkable efficacy in preclinical models of disease. MiroBio is now building out the team and the platform looking for strong antibody-development expertise to take the lead compounds to clinical proof-of-concept.
MiroBio is a well-funded spin-out from the Oxford University. The company is based in Oxford, retaining close links to the world-class immunology expertise and clinical trial experience within the University.
Reporting to: Robert Boyd – Snr Director, Preclinical
Location: Initially at the BioEscalator – Oxford
Long-term facilities will be accessible from central Oxford
Salary: Dependent on Experience
The preclinical development of antibody therapeutics requires a deep understanding of antibody pharmacology and developability. We are looking for a Senior or Principal scientist with validated experience in preclinical antibody development to support antibody pharmacodynamic/kinetic and stability studies.
This is a key role to propel our novel therapeutic antibodies from discovery to the clinic. A focus on detail and quality are essential for this role. Strong communication skills and adaptability are also requirements for this position.
Role qualification and requirements: